Synthesis, In Silico, and Biological Applications of Novel Heteroleptic Copper (II) Complex of Natural Product-Based Semicarbazone Ligands

Fekadu Muleta and Tegene Desalegn

Adama Science and Technology University, College of Applied Natural Science, Department of Applied Chemistry, Adama, Ethiopia

Correspondence should be addressed to Fekadu Muleta; muletafikadu@gmail.com

Received 17 May 2022; Accepted 29 August 2022; Published 27 September 2022

Copyright © 2022 Fekadu Muleta and Tegene Desalegn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, heteroleptic coordination between essential metallic elements with semicarbazone-based derivatives attracts more consideration for the varied ranges of bioactivities. Semicarbazone-based moiety holding azomethine (C=N) group become flexible ligands, forming stable complexes. Through a stirring and reflux technique, a novel heteroleptic complex of copper (II) was synthesized by reacting two semicarbazone-based derivative ligands, ortho-phthalaldehyde disemicarbazone (L₁) and dehydrozingerone semicarbazone (L₂), with copper chloride salt in 1:1:1 molar ratio. Magnetic moment measurement, elemental analyzer, thermogravimetric (TGA) analysis, and several spectroscopic techniques were applied to describe the prepared compounds. The disc diffusion and DPPH methods were actually used to investigate the antibacterial and antiradical potentials, respectively. The obtained data indicates the ligand (L₁) has good mean inhibition zones on Staphylococcus aureus (12.42 ± 0.00 mm) and S. pyogenes (11.64 ± 0.12 mm) bacteria. The heteroleptic [Cu(L₁) (L₂)] complex displayed higher antibacterial actions (13.67 ± 0.52 mm) on Streptococcus pyogenes bacteria. The [Cu(L₁) (L₂)] complex also shows better antiradical potential (63.7%). Furthermore, the docking result of prepared compounds on S. aureus gyrase confirms the ligands (L₁ and L₂) and the complex potential molecules possess the smallest binding potential of −8.0 to −8.4 kcal/mol. A higher value was achieved by [Cu(L₁) (L₂)] complex (−8.4 kcal/mol). Thus, this study indicates an insight towards combining semicarbazone form derivatives of natural source origin with a synthetic compound as ligands through metal coordination could enhance bioactivity.

1. Introduction

Novel concepts of complex chemistry in heteroleptic complex formation involving different ligands are an important recent idea in research because of their potential biological activities. Semicarbazone derivative-based metal-coordinated substances are important and focal points in research for bioinorganic and medicinal chemistry. These derivative forms show bioactivities, mainly antiviral [1], antibacterial, fungicidal, antioxidant [2], and antiparasitic actions [3]. But a resistance developed by microbial reduces their effectiveness greatly as for potent medicinal applicants [4]. However, the ideas of coordinated complex formation with different bioactive organic ligands were an important strategy to increase the bioactivities to tackle the resistance developed and also to overcome the rising of microbial adaption to known antibiotics. Metal-coordinated compounds possess greater activity relative to pure compounds [4]. Semicarbazone-based derivatives are synthesized by condensation through refluxing semicarbazide with suitable aldehyde/ketone groups. They work as ligands possessing heteroatoms as binding modes to metals giving a stable form of complexes. The existence of metal can promote the cytotoxicity properties of coordinated semicarbazone by increasing the membrane penetration power (lipophilicity) and actions to damage bacteria cells. This is because coordinated ligands decrease the polarity and increase the nonpolarity nature of the metal [5]. The presence of the
imine bond (-C=N-) within semicarbazone ligands plays a central role in the antibacterial mechanism of action [6]. Thus, to synthesize semicarbazone-based derivative ligands for heteroleptic complex formation, natural product origin (dehydrozingerone) and synthetic origin (ortho-phthalaldehyde) [7] were purposely focused on. Ortho-phthalaldehyde (OPA) contains two aldehyde groups that are proposed for antimicrobial action [8]. However, practically all bacteria species gain increasing resistance to its activity almost immediately [8]. It reacts with amine-containing molecules [9, 10]. Dehydrozingerone is a ketone-containing natural substance identified in the traditionally used medicinal herb ginger (Zingiber officinale) [11, 12]. These facts motivated us to develop ligands from semicarbazone-based derivatives of ortho-phthalaldehyde, dehydrozingerone, and their heteroleptic copper (II) complex to a higher extent as potent bioactive ancillary compounds, to tackle multidrug-resistant microbial pathogens.

The pharmacological studies which are a crucial tool in the current drug investigation [13, 14] were performed for the synthesized sample compounds. It comprises characteristics that are effective in identifying key bioactive compounds, such as drug-likeness, ADMET, and toxicity [14]. Selecting bioactive compounds has recently been easier to in silico techniques like docking and online ADMET predictions (Swiss ADME, Pro-Tox II, and OSIRIS property explorer) [15–17] and also to support experimental results.

Thus, a synthesis, antibacterial, antioxidant, in silico docking studies, and drug-likeness evaluations of novel heteroleptic copper (II) compounds incorporating OPA-disemicarbazone, and dehydrozingerone-disemicarbazone ligands were reported. The goal was to see how effective they were as new compounds for antibacterial and antioxidant agents created by coordinating different bioactive ligands with copper (II) metal.

2. Experimental

2.1. Materials and Methods. Analytical-reagent (AR) grade chemicals, reagents, and standard instruments were used. Semicarbazide hydrochloride, sodium acetate, glacial acetic acid, ortho-phthalaldehyde (OPA), dehydrozingerone, metal salts, methanol, diethyl ether, and ethanol were received from Alchem Pvt. Ltd., Addis Ababa. Stuart SMP 2, an electrothermal device made in the UK, was used to measure the melting points of the samples. The purity of samples during synthesis was checked by TLC run by UV254. Using a Chem LAB UV spectrometer, an absorbance measurement for the samples was made in the UV/Vis range (scan wavelength: 200.0–800.0, test mode: ABS mode) nm. The CHN analyzer performed elemental assays for C, H, and N and also together with the metal by SEM-EDX. A Perkin Elmer FT-IR spectrophotometer (400–4000 cm⁻¹), model no. BX, was used to record the FT-IR spectra data as KBr pellets. A Bruker advance 400 spectrometer running at 400 MHz was used to gather the NMR spectra data in DMSO-d₆. The XRD data were determined by Philips X-pert pro diffractometer, PW 1830. The weight loss vs temperature relationship is measured by the TGA-60H thermal analyzer.

While N₂ gas was present, the scanning was performed at a rate of 10.0 degrees per minute, until 1500 K.

2.2. Synthesis of Ortho-Phthalaldehyde Disemicarbazone Ligand (L₁). The semicarbazide moiety was prepared by following the condensation through the refluxing technique, from the raw materials ortho-phthalaldehyde and salt form of semicarbazide (Figure 1), by adopting a similar method used by Deluchat [7] and Goel et al. [18].

The semicarbazide with hydrochloride (0.01 mol and 1.11 g) prepared in 30 mL aqua ethanol was mixed with 30 mL ethanol solution of ortho-phthalaldehyde (0.005 mol and 0.67 g) together with CH₃COONa (0.01 mol and 0.82 g). The semicarbazide were generated from semicarbazide hydrochlorides by CH₃COONa. The CH₃COOH produced during the reaction progress protonates the C=O functional group of ortho-phthalaldehyde. As a result, the carbon atom has a greater ability to undergo a nucleophilic reaction. The clear solution formed was continuously stirred through refluxing at 65–70°C for around two hours. The completion and product formation were checked by spot detection using TLC. The crude product obtained was filtered, washed repeatedly with ethanol and warm water, and then dried under a vacuum desiccator over P₂O₅. Yield: 75%, color: cloudy powder, m.p = 240–242°C, and Rf = 0.41 (EtoAc: methanol = 7: 3). Elemental analysis for C₁₀H₁₂N₂O₂, (Mwt. = 248.24): Calc. %; C = 48.34, H = 4.83, N = 33.83, found; C = 47.86, H = 4.64, N = 34.02. UV-Vis (DMSO) λmax (nm) = 282 and 314. FT-IR (υ cm⁻¹, KBr): 3372 υ(N-H), 3055.4 υ(arom C-H), 1688.5 υ(C=O), 1583 υ(C=N), 1505.4 υ(arom C=C), 1088.6 υ(C-N), 1H NMR (DMSO-d₆, ppm, 400 MHz): δ = 10.44 (s, 2H, H₆), 8.33 (d, 2H, H₄), 7.87 (dd, 6.0, 3.4Hz, 2H, H₃), 7.37 (s, 2H, H₂), 6.50 (s, 4H, H₁). 13C NMR (DMSO-d₆, 101 MHz), δ = 157.2 (C-S), 138.9 (C-4), 132.4(C-3), 129.3 (C-2), and 128.3 (C-1). Rf = 0.60 (EtoAc:methanol = 7:3). Elemental composition for C₁₂H₁₅N₅O₃ (Mwt. = 249.27), Calc. %; C, 57.8; H, 6.1; N, 16.9.

2.3. Synthesis of Dehydrozingerone Semicarbazone Ligand (L₂). Semicarbazide in hydrochloride form (1.12 g) and CH₃COONa (0.82 g) by equimolar (0.01 mol) were mixed and dissolved in 30 mL distilled water within a beaker. The mixture was warmed in an oil bath up to the observation of a clear solution releasing semicarbazide from its salt form (Figure 2). Dehydrozingerone as a starting material (0.92 g) dissolved by methanol (25 ml) was gently transferred drop-by-drop to the homogenous solution and heated to the point of reflux at 70–75°C. A catalytic amount of hydrochloric acid (drop-wise) was steadily introduced in a bath under reflux for 4 h until the reaction was completed. The progress and reaction completion was confirmed by thin-layered chromatography. The final product was then refrigerated on ice, filtered, dried in vacuum desiccators, and then redissolved and crystallized from ethanol to avoid unreacted species [19]. Yield: 78.5%; color: brown powder, m.p = 170.5°C, and Rf = 0.60 (EtoAc: methanol = 7: 3). Elemental composition for C₁₂H₁₄N₃O₃ (Mwt. = 249.27), Calc. %; C, 57.8; H, 6.1; N, 16.9.
Found %; C, 57.7; H, 5.8; N, 16.2. UV-Vis (MeOH) λ<sub>max</sub> (nm): 209 and 333 (figure S2). FT-IR (ʋ cm<sup>−1</sup>, KBr): 3578 ʋ (O-H), 3485–3204 ʋ (N-H), 2929 ʋ (arom C-H), 2852 ʋ (aliph C-H), 1695.7 ʋ (C=O), 1583 ʋ (C=N), 1509 ʋ (arom C=C), and 1437 ʋ (O-H bend).

**1H NMR (DMSO-d<sub>6</sub>, 400MHz), δ/ppm:**
- 2.01 (s, H-1), 3.80 (s, H-2), 6.44 (s, H-3), 6.75–6.83 (d, H-5, H-6, J=8.2 Hz), 6.94 (s, H-8), 6.85 (d, H-4, J=16 Hz), 6.93 (d, H-7, J=16 Hz), 9.28 (s, H-9), and 9.35 (s, H-10).

**13C NMR (DMSO-d<sub>6</sub>, 101MHz) δC:**
- 11.97 (C-1), 55.97 (C-2), 110.22 (C-3), 116.07 (C-4), 120.85 (C-5), 127.01 (C-6), 128.59 (C-7), 132.23 (C-8), 146.67 (C-9), 147.46 (C-10), 148.29 (C-11), and 157.7 (C-12).

**13C-Dept (DMSO-d<sub>6</sub>, 101MHz) δC:**
- 11.98 (C-1), 55.99 (C-2), 110.24 (C-3), 116.10 (C-4), 120.26 (C-5), 127.01 (C-6), and 132.24 (C-7).

### 2.4. Synthesis of Heteroleptic Cu(II) Complex.

CuCl<sub>2</sub>·2H<sub>2</sub>O (0.001 mol, 0.17 g) was added to ethanol. With the aid of stirring, the chosen ligands were added to the solution. The mixture was refluxed for 5 hours and was stirred until the color of the solution changed. The pH of the mixture was kept at around 7.5–8 pH by adding 5% of NaOH solution through stirring for 30 minutes. The end of the reaction was confirmed by TLC, and then it was cooled and sucked. The precipitate was filtered, washed with hot water, ethanol, and recrystallized in ethanol, then put in a desiccator over CaCl<sub>2</sub> to remove moisture and dried. Then, the dried substance was preserved in a clean vial for further analysis.

### 2.4.1. Copper Complex. [Cu(L<sub>1</sub>) (L<sub>2</sub>)]; Yield: 54.6%; color: brown crystal and m.p > 300°C. Elemental analysis for C<sub>22</sub>H<sub>25</sub>N<sub>9</sub>O<sub>5</sub> Cu (Mwt. = 559.01) calculated %: C, 47.23; H, 4.47; N, and 22.54, found %: C, 46.86; H, 4.23; N, 21.98. UV-Vis: λ<sub>max</sub> (DMSO) 333.4 nm. FT-IR (KBr, ʋ cm<sup>−1</sup>): 3404 ʋ (O-H), 3267, 3146 ʋ (N-H), 2926 ʋ (arom C-H), 2851 ʋ (alph C-H), 1517 ʋ (C=N), 1024 ʋ (sym N-N), 538.4 ʋ (M-N), and 447.5 ʋ (M-O). TGA mass loss 44.5% (225.2–313 °C, 1<sup>st</sup> step, calc. 1 × C<sub>10</sub>H<sub>12</sub>N<sub>6</sub>O<sub>2</sub> = 248.8 g), 5.6% (387.3–413.9°C, 2<sup>nd</sup> step, CH<sub>3</sub> + NH<sub>2</sub> = 31.3 g), and 21.8% (497.4–586.8°C, 3<sup>rd</sup> step, 1 × C<sub>7</sub>H<sub>15</sub>O<sub>2</sub> = 122.9 g). Molar conductance (λ<sub>m</sub>) = 16.4 × 10<sup>−1</sup> cm<sup>2</sup>·mol<sup>−1</sup>·K<sup>−1</sup>. Magnetic moment: 2.18 BM.

### 2.5. Antibacterial Evaluation.

Applying the disc diffusion method, the potential of the samples to inhibit bacterial growth was examined against four Gram-positive and Gram-negative bacterial species, including Streptococcus pyogenes, Staphylococcus aureus, P. aeruginosa, and E. coli [19, 20]. The media applied for bacteria’s growth were made following the previously reported method using Mueller–Hinton agar (MHA), which is a suitable medium for the growth and susceptibility test of bacteria and together with molten nutrients, which also help support bacterial growth. DMSO was taken to be a negative control, and trimethoprim as positive control. Two distinct concentrations (100 and...
200 g/mL) of the samples were used for testing on the bacterial species. The 6 mm diameter size of paper discs were soaked with 1 mL solution of prepared compounds. The sample-soaked paper discs were placed on duplicate bacteria-growing dishes. The dishes were left at 35–37°C for around 18 hours. Then, the distance moved by the chemicals inhibiting bacteria growth was measured to evaluate the observed zone that emerged around the disc. In triplicate experiments, the distance of inhibition zone was determined, and an average was calculated.

2.6. Antioxidant Evaluations. By using the diphenylpicrylhydrazyl (DPPH) method, the radical foraging capability of the samples was examined [19]. Diphenylpicrylhydrazyl was dissolved by DMSO to prepare 0.04 mg/mL concentration and a 1 mL amount was transferred to a 4 mL solution of the sample in DMSO to prepare varied concentrations of 12.5, 25, 50, and 100 μg/mL, and control was made by pouring DPPH (1 mL) in 4 mL DMSO, and 4 mL DMSO was considered as blank. The UV-Vis spectrophotometer found in the Chem Lab was used for absorbance measurement at 517 nm after each solution was shaken and placed under a dark oven for about 30 minutes [3]. Vitamin C as standard was made at varied concentrations similar to the samples. The DPPH radical scavenging activity was calculated using the following formula [21]:

\[
\text{DPPH radical scavenging potential (\text{\%})} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100,
\]

where control is the absorbance of DPPH solution without the sample compounds and Test is absorbance of the sample with the DPPH solution.

2.7. In Silico Molecular Docking Studies. ChemDraw was used to create two-dimensional structural orientations for the produced compounds. The cofactors were modified during the optimization process to achieve a desirable stable structure possessing minimum energy. A 2D and 3D geometry for the prepared compounds was created using a straightforward structural optimization approach [16]. From the protein data bank, the specific structure of bacterium enzyme or human myeloperoxidase was loaded. Protein was produced using AutoDock 4.2.6 to eliminate the cocrystallized substrate, myeloperoxidase was loaded. Protein was produced using bank, the specific structure of bacterium enzyme or human structural optimization approach [16]. From the protein data sequence and the optimization process to achieve a desirable stable structure resulting the solvolysis process [23]. Hence, no ions were detected at the exterior coordination complex. The value obtained may be due to DMSO, which can act as a binding solvent resulting the solvolytic process [23]. The resulting complex was proposed to be formulated as \([M(L_1)(L_2)](\text{H}_2\text{O})_n\), \(M = \text{Cu}, L_1, L_2 = \text{ligands, and } X = \text{Cl}^-\).

2.8. Statistical Analysis. The analysis of the bioactivity data was conducted in triplicates and the results were given as mm (mean SD of triplicates). Using the ANOVA test, with an acceptable significance value of \(p < 0.05\), the obtained data were tested for significant differences.

3. Results and Discussion

The aldol condensation through reflux methods were applied to successfully synthesized semicarbazone-based derivative ligands (\(L_1\) and \(L_2\)) and their novel Cu(II) complex compound. The imine (\(-\text{C}=\text{N}\)-) bond formation, which is the main indication for the formation of semicarbazone-based derivative ligands was created by interacting the amine component of the semicarbazide with ketone and aldehyde groups (\(\text{C} = \text{O}\)) to yield imine (\(-\text{C}=\text{N}\)-) holding derivatives. Semicarbazide is released from semicarbazide hydrochloride when the reagent \(\text{CH}_3\text{COONa}\) is introduced during the synthesis process. The acid (\(\text{CH}_3\text{COOH}\)) produced when the reaction occurs, hydrogenates the oxygen of ortho-phthalaldehyde and dehydrozingerone and activates the C=O carbon favorable to nucleophilic reaction [22]. In solvents like water, methanol, and ethanol, the samples were only slightly dissolved; however, within DMSO all the compounds were completely dissolved.

3.1. Conductivity of the Complex. The conductivity value of \([\text{Cu}(L_1)(L_2)]\) in \(10^{-3}\) M DMSO was 16.4 \(\Omega^{-1}\cdot\text{cm}^{-2}\cdot\text{mol}^{-1}\), showing that the heteroleptic complex was nonelectrolyte, as a conductivity value below 60 \(\text{cm}^{-2}\cdot\text{mol}^{-1}\) is standard values for nonelectrolyte substance dissolved in DMSO [23]. Hence, no ions were detected at the exterior coordination complex. The value obtained may be due to DMSO, which can act as a binding solvent resulting the solvolytic process [23]. The resulting complex was proposed to be formulated as \([M(L_1)(L_2)](\text{H}_2\text{O})_n\), \(M = \text{Cu}, L_1, L_2 = \text{ligands, and } X = \text{Cl}^-\).

3.2. The UV-Vis Spectra Analysis. The UV-Vis spectra for the synthesized compounds were generated by dissolving in dimethyl sulphoxide and measured in the range of 200–800 nm. The observed band of \(L_1\) indicated by Figure S1 (see supplementary materials) shows peaks around 282.2 and 314.5 nm. The observed peak at 282.2 nm confirms the
formation of indicated in Figures 3–5. Scheme group confirming that exist in compounds. This crucial tools for determining the stretching and vibrational frequencies of bonding groups that exist in compounds. This confirmsthe binding of ligandsto copper by the oxygen of the imine (C\(-\text{N}\)) group. This v(C\(-\text{O}\)) for \(L\)\(-\text{N}\) group. This v(C\(-\text{C}\))\((\text{C} = \text{N})\) for the \([\text{Cu}(L_1)(L_2)]\) complex was at 1524 cm\(^{-1}\). This indicates the shift of frequencies by 58.9 cm\(^{-1}\), confirming that both \(L_1\) and \(L_2\) ligands were coordinated by the nitrogen of the imine group [28]. Similarly, v(C\(-\text{O}\)) for \(L_1\) and \(L_2\) were indicated at 1688.5 and 1695.5 cm\(^{-1}\), respectively, but in [Cu(L1) (L2)], it was observed at 1602 cm\(^{-1}\), lowered by 86.5 and 93.5 cm\(^{-1}\). This confirms the binding of ligands to copper by the oxygen atom. In addition, the appearance of new wave bands between 538.4 and 447.5 cm\(^{-1}\) is ascribed to v(M\(-\text{N}\)) and v(M\(-\text{O}\)) coordination [24] (Figure 5).

3.4. Elemental Analysis. The elemental composition of the compounds was generated from the CHN and EDX analysis results. The EDX spectra of the \([\text{Cu}(L_1)(L_2)]\) complex showed characteristic signals of carbon, nitrogen, oxygen, and copper. It indicates the complex is composed of CHCuNO (Figure 6). The EDX data of the complex confirms that the ligands were in a complex with copper in the sample. The calculated values were close to found (experimental) values. Furthermore, SEM was done to study the morphology and size of the crystal of the complex (Figure 7). The SEM image showed the crystallinity of particles in the complex. Thus, both the SEM image and XRD results confirm the complex has a crystalline-like structure.

3.5. NMR Data Analysis. The evidence for structural elucidation of ligands was also confirmed using both \(^1\text{H}\) and \(^{13}\text{C}\)-NMR together with \(^{13}\text{C}\) DEPT-135 data, which provides precise information about the exact positional and number of proton and carbon atom species of proposed structures. Signal protons around 6.5 and 7.37 ppm on the \(^1\text{H}\) NMR spectra of \(L_1\) were assigned to NH2 (H1) and NH (H2) protons, respectively. CH (H3) and (H4) protons were also detected at 7.87 and 8.33 ppm, respectively. The signal around 10.43 ppm validates the N=CH (H2) proton, indicating that the \(L_1\) ligand was perfectly synthesized (Figure 8).

The \(^{13}\text{C}\)-NMR graph of \(L_1\) indicated a signal found at 157.2 ppm allotted for carbon in (C=O), and a signal for carbon in (C=N) was found at 138.86 ppm. Other remaining signals observed at 128.3, 129.3, and 132.4 ppm were for carbons found on the cyclic ring, which perfectly matched the proposed structure (Figure 9).

The proton signals found around 2.01 and 3.89 ppm for \(L_2\) are ascribed to protons of the OCH3 (methoxy) group and -CH3 bound to imine carbon, respectively [19]. The carbothioamide (NH2) group proton signal is observed at 6.44 ppm. The other signals observed at 6.93 and 6.71 ppm were for ethylene group protons. The O-H and N-H protons were indicated at 9.28 and 9.35 ppm. Signals for the aromatic protons appeared at 6.94, 6.83, and 6.75 ppm as indicated in Figure 10. Furthermore, the \(^{13}\text{C}\)-NMR graph of the \(L_2\) ligand indicated a signal observed at 157.7 ppm for a carbonyl (C=O) carbon, and the carbon signal of imine (C=N) was located at 148.29 ppm. The carbons of the benzene ring attached to OCH3 and OH were observed at 147.47 and 146.66 ppm, respectively. The aliphatic (CH=C-H) carbon signals were located at 132.23 and 128.59 ppm [29]. The other signals for carbons in the ring were observed at 127.01, 120.85, 116.07, and 110.22 ppm, and the carbon signals for methoxy and methyl groups were indicated at 55.97 and 11.97 ppm (Figure 11). So, the data obtained best match the proposed structure.

3.6. Thermogravimetric Analysis of Cu(II) Complex. For metal complex compounds, the TGA, DTA, and DTG graphs provide useful geometrical data. TGA was used to approve the presence/absence of coordinate or hydrate water molecules found in the complex chemical. There is no mass loss in the thermogram graph of the heteroleptic copper (II) complex until it reaches 225°C, showing that there is no coordinated water molecule. In the first stage of breakdown, coordinated components of either \(L_1\) or \(L_2\) ligand are released from the complex. The collected TGA/DTG/DTA data are presented in Table 1, and the corresponding thermogram curves are shown in Figures 12 and 13.

The TGA curve of [Cu(L1) (L2)] complex indicates its stability until 225.2°C. It showed a mass loss of 44.5% (cal. 44.4%) within 225–314°C with a DTA peak found at 292°C. This decomposition stage confirms releasing of coordinated \(L_1\). The other ensuing steps at the second and third weight losses were 5.6% and 21.8%, respectively, totaling 27.4% (cal. 26.5%) in the region between 329 and 586.4°C confirming a release of some fragmented portion of dehydrozingerone. The remaining part was metal residue above 586.4°C.

3.7. The XRD Characterization Study. The complex sample was analyzed at 37°C by an X-ray diffractometer with Cu K\(\alpha\) radiation. The XRD array of [Cu(L1) (L2)] complex as shown in Figure S4 confirms the crystallinity of the complex. It was recorded at 2\(\theta\) ranging from 10–80° at a lambda (\(\lambda\)) value at
1.54 Å. The diffractogram for the complex showed ten reflections with maxima at \(2\theta\) (27.26 Å) equivalent to a d-value of 2.619 Å. The size of the crystal was calculated using Scherer’s formula \(Cs = \frac{K\lambda}{\beta \cos \theta}\), where \(Cs\) = crystal size, \(k\) is constant \((k = 0.94)\), \(\beta\) is width at half maxima of all peaks by the XRD array, \(\lambda\) is a wavelength used \((\lambda = 0.154\) nm) while \(\theta\) is Bragg angle. Then, diffraction arrays were successfully done by a computer program. Accordingly, the size of the crystal of the novel mixed copper complex obtained was 46.72 nm.

Thus, according to the characterization findings, the produced complex was written as \([\text{Cu}(L_1)(L_2)]\). As a result, a structure for the synthesized complex was postulated based on spectral studies, elemental analysis, SEM-EDX, XRD, magnetic investigations, TGA data, and physical parameters (Figure 14).

3.8. Antibacterial Evaluations. The bioactive imine (-N=CH-) group in semicarbazones as an organic ligand is what gives them their main biological activity. The imine group facilitates different mechanistic actions in biological systems. It makes the semicarbazone-based derivatives active in a living system. Hence, in order to create the best
bioactive drug candidates vs. bacterial species, the synthesized sample ligands and their complex were tested for antibacterial activity, and the results are presented in Table 2.

The data revealed that the samples had medium to higher activities on the bacteria strains. $L_1$ shows a higher mean distance of inhibition on $S. aureus$ bacteria (12.42 ± 0.23 mm at 200 $\mu$g/mL). The complex [Cu($L_1$) ($L_2$)] showed higher activity on $S. pyogenes$ (13.67 ± 0.52 mm at 200 $\mu$g/mL) than the ligands and was comparably relative to trimethoprim (16.71 ± 0.77 mm). It also displayed that a complex showed higher results than the constituent ligands for all bacteria strains at similar concentrations. The obtained data conclude that metal complexed to bioactive ligands enhances their activities to inhibit bacterial progression and induces potential for growth inhibition. Furthermore, the activity of all
the samples was directly proportional to their concentration (Figures 15 and 16).

3.9. Antioxidant Evaluations. The antiradical nature of the samples was studied to explore their abilities relative to the standard with an expectation of developing active molecules against radical species. The data are concluded in Table 3 and related to a standard as displayed in Figure 17.

From the results concluded in Table 3, the complex ([Cu(L1)(L2)]) showed the best potential with maximum scavenging activities than the ligands (60.4–63.7%) close to ascorbic acid, and the least activity (32.60%–40.34%) was achieved by L1. The scavenging activities were roughly concentration dependent, as concentration raises, the activities were also raising. It can be also concluded from the table, that the complex possesses higher radical scavenging properties than the constituent ligands. This may be due to the electron-deficient nature of the metals compared to their ligands.

3.10. Molecular Docking Studies

3.10.1. The Binding Interaction Studies on S. aureus gyrase. The S. aureus gyrase is a crucial enzyme in bacteria species for its survival. It kept bacteria DNA from damage during copying and imitations of the DNA strands [30]. Hence, stopping and interrupting the function of this enzyme is vital to be considered as a target for the antibacterial drug test. Thus, under this investigation, docking studies were done to examine their interaction and configuration with S. aureus gyrase (Figures 18–20). The docking results were compared with trimethoprim (Table 4).

Table 4 presented the lowermost binding energy of the prepared samples on the bacterial enzyme was found between −8.0 and −8.4 kcal/mol. The [Cu(L1)(L2)] complex displays the best binding (−8.4 kcal/mol) affinity. Relative to trimethoprim which had a binding potential of −7.9 kcal/mol, the samples achieved good interaction affinities and similar interaction profiles with amino acid residues. The [Cu(L1)(L2)] complex possesses more additional H-bonding interactions. The overall docking results obtained match with in vitro data. Hence, the compounds are able to be considered antibacterial drug candidates with few modifications.

Figures 18–20 depict the information discovered under Table 4 using 2D, 3D model binding, and a 3D ribbon, model on S. aureus gyrase. H-bonds were shown by green,
hydrophobic by pink, and pi-cation by orange colors, and the varied bonds that were induced between the samples and amino acids were shown by different colors.

3.10.2. The Binding Manner of Samples Docked against Myeloperoxidase. The binding manner of the samples put inside the sites of myeloperoxidase was investigated compared to ascorbic acid, see supplementary materials as shown in Figures S5, S6, and S7. It showed that the compounds show comparable binding nature ($-7.9$ to $-9.5$ kcal/mol) relative to vitamin C ($-8.1$ kcal/mol). The [Cu($L_1$) ($L_2$)] complex and $L_1$ showed the best binding capability of $-8.5$
and −9.5 kcal/mol orderly. The \([\text{Cu}(L_1) \ (L_2)]\) complex has shown binding through hydrogen bonding with His-95, His-336, Thr-329, and Asp-98 residues similar to vitamin C (Table 5). The antiradical potential results were best correlated with the sample compounds that had good docking marks. As a result, the compounds could be useful as
antiradical agents. Table 5 summarizes the information gathered and Figures S5–S7 (see supplementary materials) depicted the 2D, 3D mode of binding or 3D ribbon, and mark models.

3.10.3. Toxicity and Drug Similarity (Pharmacokinetics) Studies. If bioactive compounds meet “Lipinski’s rule of five” [31], they are considered a promising drug candidate. As a result, the ligands’ drug-likeness (pharmacokinetics) qualities were addressed by the rule. The criterion stipulates that prospective therapeutic compounds must have fewer than 10 H-bond acceptors (HBAs), fewer than 5 hydrogen-bond donors (HBDs), fewer than 5 log $P$, fewer than 500 Da molecular mass, and fewer than 140 Å overall polarity nature [32]. The results from the Swiss ADME workout (Table 6) demonstrate that the tested substances meet the criteria with zero violations.

Analyses of a compound’s ADME are a crucial metric in the research of bioactive pharmacological agents. Tables 7 and 8 highlight the ADME features of the substances in comparison to the reference medications (trimethoprim and
Figure 14: Proposed structures for $[\text{Cu}(L_1)(L_2)]$ complex.

Figure 15: Inhibition zone plot of the samples on bacterial growth (mean ± SD).

Figure 16: Distance moved by samples inhibiting the growth of $S. aureus$, where C and $C^*$ and L and $L^*$ are concentrations of the complex and ligands at 100 and 200 $\mu$g/mL, respectively.
The presence of a significant $\log Kp$ value in the sample compounds confirms that they are not absorbed via the skin. $L_1$ had equivalent skin absorption to the trimethoprim ($-8.33$ and $-8.54$ cm/s); however, $L_2$ and $[\text{Cu}(L_1)(L_2)]$ had greater skin fascination values ($-7.15$ and $-7.45$ cm/s). Moreover, both ligands and the $[\text{Cu}(L_1)(L_2)]$ complex demonstrated substantial GI absorption but no BBB absorption.

Depending on toxicity classes (1 (toxic) to 6 (nontoxic)) and LD$_{50}$ data found in Table 8, it can be confirmed that the samples did not show severe toxicity compared to the standard drugs. $L_1$ has displayed class 4 toxicity (not safe for
swallowing), and $L_2$ displayed better class 5 toxicity properties. Both ligands were considered noncytotoxic. Consequently, the compounds may be regarded as the top drug candidates based on the data analysis.
### Table 4: The docking results of the samples on bacterial enzyme.

| S. No. | Compounds | Binding affinities (kcal/mol) | H-bonds | Residual interactions | Van der Waals |
|--------|-----------|-------------------------------|---------|-----------------------|---------------|
| 1      | \( L_1 \) C\(_{10}\)H\(_{12}\)N\(_6\)O\(_2\) | \(-8.2\) | Lys-460, Arg-458:O, Arg-458:CD, DG-9, DT-10, DA-11, DC-12, and DA-13 | T-shaped-DA-13, Alkyl-Arg-458 | Gly-459, Asn-475, Glu-477, Ile-461, and DC-14 |
| 2      | \( L_2 \) C\(_{12}\)H\(_{15}\)N\(_3\)O\(_3\) | \(-8.0\) | Ser-1084: HG, Ser-1084: OG, Arg-458:CD, Arg-458:O, Arg-1122, Glu-477, DA13:N3, and DA-13: O4' DT-8 | Pi-cation-DA-13(Dist. 4.12239 Å), Pi-sigma-DA-13, pi-pi DG-9, pi-pi DA-13(Dist. 5.19252 Å), and pi-Alkyl-DA-13(Dist. 4.36677 Å) | Gly-1082 and DG-12 |
| 3      | [Cu(\( L_1 \)) (\( L_2 \))] C\(_{22}\)H\(_{25}\)N\(_9\)O\(_5\)Cu | \(-8.4\) | Ser-438:HN, Ser-438: OG, Asp-1083 (Dist. 2.81399 Å), Asp-1083 (Dist. 3.3489 Å), DG-9: O6, and DG-9: N7 | Pi-sigma-Ala-1120, pi-Sigma-Met-1121, Alkyl-Ala-1120, Alkyl-Met-1121, Alkyl-Arg-1122, pi-Alkyl-Ala-1120 | Tyr-1087, Ser-1084, Glu-1088, Ala-1118, Ala-1119, Gly-1117, Met-1075, and Phe-1123, Asp-437 |
| 4      | Trimethoprim C\(_{14}\)H\(_{18}\)N\(_4\)O\(_3\) | \(-7.9\) | Arg-458: DT-8, HH11, Arg-458: DG-9, CD, and DC-12 | Electrostatic-pi-anion-Asp-94, Hydrophobic-pi-Alkyl-Arg-333: CA | His-336, Phe-329, His-95, Thr-329, and Asp-98 |

DA = deoxyadenosine, DT = deoxythymidine, DG = deoxyguanosine, and DC = Deoxycytidine.

### Table 5: Docking result of the sample on human myeloperoxidase.

| S. No. | Compounds | Binding affinities (kcal/mol) | H-bonds | Residual interactions | Van der Waals |
|--------|-----------|-------------------------------|---------|-----------------------|---------------|
| 1      | \( L_1 \) C\(_{10}\)H\(_{12}\)N\(_6\)O\(_2\) | \(-7.9\) | Gly-155, Ser-156, Arg-161, Arg-148, Ser-42, and Cso-151 | Pi-cation-Arg-148, electrostatic-pi-cation-Arg-161, pi-Alkyl-pro-123, and pi-Alkyl-Arg-148 | Leu-43, Trp-47, Pro-124, Pro-103, Glu-102, Ser-149, Pro-151, Pro-154, and Cys-153 |
| 2      | \( L_2 \) C\(_{12}\)H\(_{15}\)N\(_3\)O\(_3\) | \(-8.5\) | Arg-333, Asp-94, Asp-98, Gly-335: CA, Tyr-296, Phe-332, and Gly-335 | Electrostatic-Asp-94, attractive charge-Asp-98, pi-Sulfur-Met-87 | Thr-329, His-95, Ile-339, Arg-239, His-336, Gln-91, and Leu-338 |
| 3      | [Cu(\( L_1 \)) (\( L_2 \))] C\(_{22}\)H\(_{25}\)N\(_9\)O\(_5\)Cu | \(-9.5\) | Gln-91, Arg-333: HH12 Arg-333: HH22, Arg-424, Thr-100, Thr-100, and Glu-242 | Asp-94, Arg-333, and Glu-102 | Asp-98, Phe-99, His-95, Arg-332, Thr-329, Pro-101, His-336, Ile-339, His-428, Asn-421, Leu-420, Leu-147, Phe-407, Ala-104, and Glu-116 |
| 4      | Ascorbic acid (C\(_6\)H\(_8\)O\(_6\)) | \(-8.1\) | Gln-91, Arg-239, Arg-333, Thr-100, Arg-333, and Arg-333: CA | Electrostatic-pi-anion-Asp-94 | His-336, Phe-99, Phe-329, His-95, Thr-329, and Asp-98 |

### Table 6: Drug-likeness analysis of \( L_1 \) and \( L_2 \) estimation by Swiss ADME.

| S. No. | Ligands | Mass (g/mol) | NHD | NHA | NRB | TPSA (Å²) | Log P (iLOGP) lipophilicity | Log S (ESOL) water solubility | Synthetic convenience | Lipinski’s rule (zero violations) |
|--------|---------|--------------|-----|-----|-----|-----------|---------------------------|-----------------------------|--------------------------|---------------------------|
| 1      | \( L_1 \) | 248.24       | 4   | 4   | 6   | 134.96    | -0.43                     | -0.78                      | 2.37                     | 0                         |
| 2      | \( L_2 \) | 249.27       | 3   | 4   | 5   | 96.94     | 1.42                      | -1.90                      | 2.80                     | 0                         |
| 3      | [Cu(\( L_1 \)) (\( L_2 \))] | 559.01 | 4   | 4   | 5   | 102.6     | 1.46                      | -2.05                      | 3.05                     | 0                         |
| 4      | Trimethoprim | 290.32 | 2   | 5   | 5   | 105.51    | 2.21                      | -2.31                      | 2.58                     | 0                         |
| 5      | Ascorbic acid | 176.12 | 4   | 6   | 2   | 107.22    | -0.31                     | 0.23                       | 3.47                     | 0                         |

(NHD) = number of hydrogen donors, (NRB) = number of rotatable bonds, (NHA) = number of hydrogen acceptors, and (TPSA) = total polar surface area.
4. Conclusions

Semicarbazone-based derivatives from synthetic and natural sources are effective scaffolds for developing bioactive ligands that can form stable complexes with metals. Both ligands form a complex with copper via nitrogen (-C=N) and carbonyl oxygen (-C=O) atoms. The geometrical configurations of [Cu(L_1) (L_2)] appear to be octahedral based on electronic (UV-vis) spectra information and the magnetic moment of a complex. Furthermore, conductivity results for the [Cu(L_1) (L_2)] complex indicate values of less than 60_1 cm^-2 mol^-1, indicating that the complex generated was neutral, possessing no free anions outside the complex sphere. Within similar examination conditions, the antimicrobial potential data demonstrates that the [Cu(L_1) (L_2)] complex has a stronger antibacterial and antioxidant action potential than both constituent ligands. Compounds having good binding affinity, zero violations of Lipinski’s assertion, and best coherence with antibacterial and antioxidant assay results in vitro were discovered using docking and drug-likeness ADME data. As a result, the ligands and the complex show a promise as antibacterial and antioxidant chemicals, with potential to be further refined for use as therapeutic molecules.

Data Availability

The data are included in the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors would like to acknowledge Wolaita Sodo University and Adama Science and Technology University for technical as well as material support.

Table 7: ADME expectations worked out by Swiss ADME and preADMET.

| S. No. | Ligands | SPV (LogKp) cm/s | GIA BBBp | Pgps | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor |
|--------|---------|-----------------|----------|------|-----------------|-----------------|-----------------|-----------------|-----------------|
| 1      | L_1     | -8.33           | High     | No   | No              | No              | No              | No              | No              |
| 2      | L_2     | -7.15           | High     | No   | No              | No              | No              | No              | No              |
|        | [Cu(L_1) (L_2)] | -7.45       | High     | No   | No              | No              | No              | No              | No              |
| 3      | Trimethoprim | -7.42         | High     | Yes  | No              | No              | No              | No              | No              |
|        | Ascorbic acid | -8.54         | High     | No   | No              | No              | No              | No              | No              |

SPV = skin permeability value, CYP = cytochrome-P, BBB = blood brain barrier permeability, GIA = gastrointestinal, and P-gp = P-glycoprotein substrate.

Table 8: Toxicity properties.

| S. No. | Compounds | LD_{50} (mg/kg) | Toxicity classes | Hepatotoxicity | Carcinogenicity | Immunotoxicity | Mutagenicity | Cytotoxicity | Irritant |
|--------|-----------|-----------------|------------------|----------------|----------------|----------------|--------------|--------------|
| 1      | L_1       | 500             | 4                | Active         | Active         | Inactive       | Active       | Active       | No       |
| 2      | L_2       | 1560            | 5                | Active         | Active         | Active         | Active       | Inactive     | No       |
|        | [Cu(L_1) (L_2)] | 2000          | 4                | Inactive       | Inactive       | Inactive       | Inactive     | Inactive     | No       |
| 3      | Trimethoprim | 3500           | 5                | Inactive       | Active         | Active         | Inactive     | No           | No       |
|        | Ascorbic acid | 3367           | 5                | Inactive       | Inactive       | Inactive       | Inactive     | Inactive     | No       |

Supplementary Materials

Figure S1: the UV-Vis graph of L_1, Figure S2: the UV-Vis graph of L_2, Figure S3: the UV-Vis graph of the [Cu(L_1) (L_2)] complex, Figure S4: the XRD pattern of the Copper (II) complex, Figure S5: the 2D and 3D binding sites of L_1, Figure S6: the 2D and 3D binding mode of compound L_2, and Figure S7: the 2D and 3D binding mode of reference drug ascorbic acid. (Supplementary Materials)

References

[1] S. M. Dawoud, “Synthesis and DNA binding study of Co (II) and V (IV) complexes with O, N, O tridentate 3-methoxysalicylaldehyde-semicarbazide based ligand,” *Journal of Physics: Conference Series*, vol. 1879, no. 2, Article ID 022059, 2021.

[2] D. Sarker, M. R. Karim, M. M. Haque, R. Zamir, and M. A. Asraf, “Copper (II) complex of salicylaldehyde semicarbazone: synthesis, characterization and antibacterial activity,” *Asian Journal of Chemical Sciences*, vol. 6, no. 4, pp. 1–8, 2019.

[3] A. H. El-Ghorab, M. Nauman, F. M. Anjum, S. Hussain, and M. Nadeem, “A comparative study on chemical composition and antioxidant activity of ginger (Zingiber officinale) and cumin (Cuminum cyminum),” *Journal of Agricultural and Food Chemistry*, vol. 58, no. 14, pp. 8231–8237, 2010.

[4] A. Choudhary, R. Sharma, M. Nagar, M. Mohsin, and H. S. Meena, “Synthesis, characterization and antioxidant activity of some transition metal complexes with terpenoid derivatives,” *Journal of the Chilean Chemical Society*, vol. 56, no. 4, pp. 911–917, 2011.

[5] S. Ahmad, A. A. Isah, S. Ali, and A. R. Al-Arfaj, “Perspectives in bioinorganic chemistry of some metal based therapeutic agents,” *Polyhedron*, vol. 25, no. 7, pp. 1633–1645, 2006.

[6] E. Bahojb Noruzi, B. Shaabani, S. Geremia, N. Hickey, P. Nitti, and H. S. Kafil, “Synthesis, crystal structure, and biological activity of a multidentate calix [4] arene ligand doubly functionalized by 2-hydroxybenzene-diene-thiosemicarbazone,” *Molecules*, vol. 25, no. 2, p. 370, 2020.
M. Balouiri, M. Sadiki, and S. K. Ibnsouda, "Methods for...

M. Simões, L. C. Simões, S. Cleto, I. Machado, M. O. Pereira, and M. J. Vieira, "Antimicrobial mechanisms of ortho-phthalaldehyde action," Journal of Basic Microbiology, vol. 47, no. 3, pp. 230–242, 2007.

S. Yogosawa, Y. Yamada, S. Yasuda, Q. Sun, K. Takizawa, and T. Sakai, "Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells," Journal of Natural Products, vol. 75, no. 12, pp. 2088–2093, 2012.

G. A. Hampannavar, R. Karpormath, M. B. Palkar, and M. S. Shaikh, "An appraisal on recent medical perspective of curcumin degradant: dehydrozingerone (DZG)," Bioorganic & Medicinal Chemistry, vol. 24, no. 4, pp. 501–520, 2016.

A. Awasthi, M. Lohani, M. K. Singh, A. T. Singh, and M. Jaggi, "Pharmacokinetic evaluation of C-3 modified 1, 8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding," Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 29, no. 5, pp. 710–721, 2014.

A. Daina, O. Michielin, and V. Zoete, "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules," Scientific Reports, vol. 7, no. 1, pp. 42717–42813, 2017.

P. Banerjee, A. O. Eckert, A. K. Schrey, and R. Preissner, "ProTox-II: a webserver for the prediction of toxicity of chemicals," Nucleic Acids Research, vol. 46, no. W1, pp. W257–W263, 2018.

A. Garg, A. Tadesse, and R. Eswaramoorthy, "A four-component domino reaction: an eco-compatible and highly efficient construction of 1, 8-naphthyridine derivatives, their in silico molecular docking, drug likeness, ADME, and toxicity studies," Journal of Chemistry, vol. 2021, Article ID 5589837, 16 pages, 2021.

O. Trot and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.

S. Goel, S. Chandra, and S. D. Dwivedi, "Synthesis, spectral and biological studies of copper (II) and iron (III) complexes derived from 2-acetyl benzofuran semicarbazone and 2-acetyl benzofuran thiosemicarbazone," Journal of Saudi Chemical Society, vol. 20, no. 6, pp. 651–660, 2016.

F. Muleta, T. Desalegn, R. Eswaramoorthy, and A. Garg, "Synthesis, characterization, in-silico, and in-vitro biological studies of Cu (II), Zn (II) complexes of semicarbazone, thiosemicarbazone derivatives of dehydrozingerone," Journal of Molecular Structure, vol. 1268, Article ID 133632, 2022.

M. Balouiri, M. Sadiki, and S. K. Ibnsouda, "Methods for in vitro evaluating antimicrobial activity: a review," Journal of Pharmaceutical Analysis, vol. 6, no. 2, pp. 71–79, 2016.

S. Dutta, S. Padhye, K. I. Priyadarshini, and C. Newton, "Antioxidant and antiproliferative activity of curcumin semicarbazone," Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 11, pp. 2738–2744, 2005.